FDA Expands Monoclonal Antibody Indications to Post Exposure Prophylaxis In Non-vaccinated Individuals

The use of Casirivimab/Imdevimab has been authorized for emergency use to treat mild to moderate COVID-19 in adult and pediatric patients with positive results of SARS-CoV-2 viral testing who are 12 years of age or older, weighing at least 40 kg, and who are at high risk of progressing to severe COVID-19 and/or hospitalization. Synergy … Read more